Bayer is boosting its precision oncology efforts with a molecular database from health tech firm ConcertAI.  | Bayer is ...

Two prominent German investors voiced exasperation over Bayer AG’s recurring struggles, demanding a clearer path out of the ...

The firms will explore molecular mechanisms and patient responses in cancer to inform development of new therapies.

The expansion strengthens Bayer’s ability to deliver health-focused products more efficiently across North America.

Bayer BAYRY announced that the FDA has granted full approval to oncology drug, Vitrakvi (larotrectinib), a first-in-class TRK inhibitor. The drug is now fully approved in the United States for ...

The U.S. Food And Drug Administration (FDA) granted full approval to Bayer AG’s (OTC:BAYRY) Vitrakvi (larotrectinib) for adult and pediatric patients with solid tumors that have a neurotrophic ...

Underestimation of low-cost, effective interventions such as aspirin may cause considerable harm. This editorial seeks to review the impact of dosage, timing and adherence to aspirin on its efficacy ...

German drug maker Bayer, which is awaiting regulatory approval for its new drug, elinzanetant, expects it to hit the market soon. This latest non-hormonal treatment is anticipated to be superior ...

“Aspirin is a well-established and a safe medical medication with well-known side effects. The incidence of adverse events was as expected," noted Martling.

The idea that aspirin is such a “wonder drug” is the subject of intense research, but the picture is muddled. The notion that aspirin could have anti-cancer properties dates back decades.